These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19066269)

  • 1. Nonhormonal systemic therapy for advanced breast cancer: do the math!
    Bedard PL; Piccart-Gebhart MJ
    J Natl Cancer Inst; 2008 Dec; 100(24):1745-7. PubMed ID: 19066269
    [No Abstract]   [Full Text] [Related]  

  • 2. [Should chemotherapy or endocrine therapy be used as first choice in patients with advanced breast cancer? A status article based on the Cochrane analysis "Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer"].
    Ejlertsen B; Mouridsen H
    Ugeskr Laeger; 2004 Jun; 166(25):2434-6. PubMed ID: 15283108
    [No Abstract]   [Full Text] [Related]  

  • 3. Anthracyclines in the treatment of HER2-negative breast cancer.
    Paik S; Taniyama Y; Geyer CE
    J Natl Cancer Inst; 2008 Jan; 100(1):2-4. PubMed ID: 18159066
    [No Abstract]   [Full Text] [Related]  

  • 4. Anthracycline therapy may be avoidable in early breast cancer, new studies suggest.
    Tuma R
    J Natl Cancer Inst; 2008 Apr; 100(7):459-61. PubMed ID: 18364497
    [No Abstract]   [Full Text] [Related]  

  • 5. Current management of advanced breast cancer.
    Hortobagyi GN; Piccart-Gebhart MJ
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):1-5. PubMed ID: 8893891
    [No Abstract]   [Full Text] [Related]  

  • 6. High-dose chemotherapy for breast cancer.
    Wheatley K; Gray RG; Ives NJ
    N Engl J Med; 2003 Oct; 349(15):1476-9; author reply 1476-9. PubMed ID: 14534343
    [No Abstract]   [Full Text] [Related]  

  • 7. Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma.
    Altundag K; Elkiran ET; Altundag O
    Cancer; 2004 Apr; 100(8):1768-9; author reply 1769. PubMed ID: 15073872
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy.
    Andreopoulou E; Hortobagyi GN
    J Clin Oncol; 2008 Aug; 26(22):3660-2. PubMed ID: 18669447
    [No Abstract]   [Full Text] [Related]  

  • 9. Predicting responses to chemotherapy in breast cancer: from bench to bedside.
    Akashi-Tanaka S
    Breast Cancer; 2010 Apr; 17(2):92-6. PubMed ID: 19789951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].
    Iizuka M; Sengoku N; Nakakuma T; Yoshimura N; Hayashi K; Enomoto T; Kuranami M; Watanabe M
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2228-30. PubMed ID: 19106579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A biological approach to breast cancer.
    Wall P
    Radiography; 1986; 52(603):125-30. PubMed ID: 3749491
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of systemic chemotherapy on clinical status and biological and immunologic markers in patients with breast cancer].
    Orlova RV; Chernetsova LF; Matveeva ON
    Vopr Onkol; 2007; 53(4):414-8. PubMed ID: 17969403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthracycline war: no victor yet.
    Young P
    J Natl Cancer Inst; 2009 Sep; 101(17):1171-3. PubMed ID: 19706625
    [No Abstract]   [Full Text] [Related]  

  • 14. Re-searching anthracycline therapy.
    Oakman C; Moretti E; Di Leo A
    Breast Cancer Res Treat; 2010 Aug; 123(1):171-5. PubMed ID: 20549335
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictive value of eIF4E reduction after neoadjuvant therapy in breast cancer.
    Hiller DJ; Chu Q; Meschonat C; Panu L; Burton G; Li BD
    J Surg Res; 2009 Oct; 156(2):265-9. PubMed ID: 19665145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New advances in the management of metastatic breast cancer.
    Glück S
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S12-6. PubMed ID: 16280104
    [No Abstract]   [Full Text] [Related]  

  • 17. Tissue inhibitor metalloproteinase type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer.
    Schmitt M; Sweep FC
    Eur J Cancer; 2009 Sep; 45(14):2444-6. PubMed ID: 19647994
    [No Abstract]   [Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy for locally advanced breast cancer.
    Specht J; Gralow JR
    Semin Radiat Oncol; 2009 Oct; 19(4):222-8. PubMed ID: 19732686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of a gene expression profile on breast cancer decisions.
    Henry LR; Stojadinovic A; Swain SM; Prindiville S; Cordes R; Soballe PW
    J Surg Oncol; 2009 May; 99(6):319-23. PubMed ID: 19204954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. End of high-dose chemotherapy for high-risk breast cancer patients?
    Tuma RS
    J Natl Cancer Inst; 2008 May; 100(9):618-9. PubMed ID: 18445811
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.